Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of lenalidomide when given
together with cyclophosphamide and to see how well they work in treating patients with
previously treated hormone-refractory prostate cancer. Lenalidomide may stop the growth of
prostate cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as
cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
lenalidomide together with cyclophosphamide may kill more tumor cells.